Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.69 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.69 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17723897 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2SMPD1MAOBNR4A2 | |
| SCHEMBL19213009 | 0.81 | MAOB (0.55) | CYP11B1CYP11B2MAOBNR4A2RAB9A | |
| SCHEMBL30392119 | 0.79 | SMPD1 (0.74) | CYP11B1CYP11B2SMPD1MAOBNR4A2 | |
| SCHEMBL25214512 | 0.79 | SMPD1 (0.74) | CYP11B1CYP11B2SMPD1MAOBNR4A2 | |
| SCHEMBL19212982 | 0.78 | CYP11B1 (0.65) | CYP11B1CYP11B2MAOB | |
| SCHEMBL4684138 | 0.76 | MRGPRX4 (0.70) | NR4A2RAB9AMRGPRX4 | |
| SCHEMBL19212927 | 0.76 | CYP11B1 (0.68) | CYP11B1CYP11B2RAB9AMRGPRX4 | |
| SCHEMBL8193954 | 0.76 | NR4A2 (0.72) | SMPD1MAOBNR4A2SRD5A2PTPN1 | |
| SCHEMBL8189375 | 0.76 | NR4A2 (0.77) | SMPD1MAOBNR4A2SRD5A2PTPN1 | |
| SCHEMBL403151 | 0.75 | MAOB (1.00) | MAOBNR4A2RAB9AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212636-B1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-9790217-B2 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | PDXK, PNPO, PAH | CYP11B1 84/4885CYP11B2 32/4885SMPD1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.